# Sermorelin: Research Overview — Ascent Peptides > A literature summary of Sermorelin — the 1-29 GHRH fragment, formerly FDA-approved for pediatric GH deficiency, now handled as a compounded bulk. Covers mechanism, clinical history, and current regulatory nuance. The shortest peptide that retains full GHRH activity — once an approved drug, now a compounded bulk, always asking the question of how much upstream stimulation is enough. ## The short version Sermorelin is the first 29 amino acids of growth hormone-releasing hormone — the minimum fragment that still binds the GHRH receptor and triggers GH release with full potency. Because it acts upstream on the pituitary rather than supplying exogenous GH, the body's own somatostatin feedback and IGF-1 feedback loop remain intact, preserving the natural pulsatile rhythm of GH secretion [10]. Sermorelin has a specific and important history: it was the active ingredient in a drug called Geref, FDA-approved for treating idiopathic GH deficiency in children. Geref was withdrawn from the US market in 2008 for commercial reasons — not because of safety or efficacy problems [10]. The compound is now available through compounding pharmacies and is classified as a Category 1 bulk substance under the FDA's interim 503A policy, a status that should not be conflated with the situation of other GH-axis peptides reviewed at the 2024 Pharmacy Compounding Advisory Committee. This page describes the research record honestly, including where it was studied for adults and where it was not. It contains no human dose. ## What it is Sermorelin is an amidated synthetic 29-amino-acid peptide corresponding to the N-terminal 1-29 fragment of endogenous 44-residue human GHRH. The amide group on the C-terminus is the same modification found in natural GHRH and contributes to receptor binding. You will also see it called GHRH(1-29), GRF(1-29), or GRF(1-29)NH2 — all refer to the same sequence. The precise clinical context for its approved indication: as Geref, sermorelin acetate was approved under NDA 020443 for the treatment of idiopathic growth hormone deficiency and short stature in prepubertal children. That approval was withdrawn in 2008 for commercial reasons. The compound is now manufactured by compounding pharmacies and is treated as a long-standing Category 1 bulk drug under the FDA's interim Section 503A policy (final guidance January 2025). ## How it works Sermorelin binds the GHRH receptor (GHRH-R) on anterior-pituitary somatotroph cells, activating the adenylate cyclase / cAMP / PKA pathway that stimulates both the synthesis and pulsatile release of the body's own growth hormone. Because the signal travels through the pituitary's own feedback machinery — somatostatin from the hypothalamus and IGF-1 from the liver both continue to exert their braking effects — the natural pulsatile pattern of GH secretion is preserved. This is the feature that editorialists have pointed to as sermorelin's physiologic advantage: rather than bypassing the axis with exogenous GH, it works upstream, leaving the feedback circuits intact. A 2006 editorial in Clinical Interventions in Aging argued specifically that this upstream mechanism makes sermorelin a potentially more physiologic approach to adult-onset GH insufficiency than recombinant GH, because the pituitary's own safety valves remain in place [10]. A 2025 Nature Reviews Endocrinology review situates this class of compounds in the broader GHRH-receptor pharmacology, covering agonist and antagonist landscapes [1]. ## What the research shows *Pediatric GH deficiency.* In a multicenter trial of prepubertal GH-deficient children, once-daily subcutaneous GHRH(1-29) accelerated linear growth: first-year height velocity rose from approximately 4.1 cm/year at baseline to roughly 7–8 cm/year, without generating excessive IGF-1 [11]. This is the foundational clinical efficacy dataset for sermorelin as an approved compound. *GHRH-analog cognition and body-composition data.* A 2012 randomized, double-blind, placebo-controlled trial in 152 older adults (including 66 with mild cognitive impairment) used a GHRH analog (tesamorelin, a full-length 44-residue compound) rather than sermorelin, but it provides important context for the class: 20 weeks of daily subcutaneous GHRH-analog stimulation favorably affected cognition (P=0.03), raised IGF-1 by 117% within the physiologic range, and reduced percent body fat by 7.4% [8]. These findings belong to the broader GHRH-analog category; they are not direct sermorelin efficacy data. *Caution on anti-aging use.* A 2008 Annals of Internal Medicine editorial by Blackman explicitly judged the use of growth hormone secretagogues to prevent or treat the effects of aging as "not yet ready for prime time," noting that rigorous long-term efficacy and safety data for that purpose were lacking [9]. That judgment applies to sermorelin specifically and to the class generally. *Physiologic framing.* The Walker editorial in Clinical Interventions in Aging makes the case that sermorelin's upstream pituitary mechanism preserves physiologic feedback and may be better suited to adult-onset GH insufficiency than exogenous GH replacement [10]. ## Reported effects, cautions and safety Several controversies attach to sermorelin that are worth reading carefully: - *Anti-aging marketing outruns evidence.* Sermorelin is widely promoted for body composition and anti-aging benefits in adults. A leading editorialist explicitly judged this use not yet justified by evidence [9]. Long-term large-scale trial data for adult wellness use are absent. - *Approval history is often misstated.* The compound was FDA-approved as Geref (NDA 020443) and was withdrawn in 2008 for commercial reasons, not safety or efficacy failures. It is not a dangerous or banned drug; it simply no longer has a branded product [10]. - *Compounding status requires precision.* Sermorelin's Category 1 503A status is distinct from the situation of other GH-axis peptides reviewed at the 2024 PCAC — a conflation common in popular summaries. - *Oral and sublingual products.* Oral, sublingual and troche sermorelin formulations circulate widely and are widely criticized as ineffective; peptides are degraded in the gut, and the intranasal bioavailability of GHRH(1-29) is very low (~3–5%) [10]. - *Doping prohibition.* GH secretagogues including GHRH analogs are prohibited in sport under WADA; dedicated LC-MS/MS detection methods exist for sermorelin and related compounds. - *GH/IGF-1 cancer concern.* Chronically elevated GH and IGF-1 are mitogenic; this is a recognized theoretical risk for any GH-axis intervention, even one that works through the body's own pulsatile release [1]. ![Sermorelin peptide chain and anterior-pituitary signaling cascade in glacier tones](/images/sermorelin.webp) ## Where it fits in GH-axis research Sermorelin is the natural-fragment anchor of this desk — the compound that stays closest to what the hypothalamus actually sends. Where [CJC-1295](/cjc-1295) extends that signal for days through albumin tethering, and [Tesamorelin](/tesamorelin) modifies the full-length sequence for DPP-IV resistance, sermorelin simply is the minimum active sequence, minimally modified [1]. Its approved history in pediatric GH deficiency gives it the most grounded clinical backstory of the three, even as its adult evidence base remains thinner than its popularity in research communities would suggest [9]. See how it lines up against the others on the [comparison page](/compare). --- A literature digest tracing three GHRH analogs through the peer-reviewed record — mechanism, evidence, and caution, but never a dose or a product.